Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure

被引：0
|
作者：
Gupta, A. [1 ]
Laheru, D. [1 ]
机构：
[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1680P
引用
下载
收藏
页码：S921 / S921
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence
    Gupta, Amol
    De Jesus-Acosta, Ana
    Le, Dung
    Pishvaian, Michael
    Zaidi, Neeha
    Zheng, Lei
    Laheru, Daniel
    CANCER, 2024,
  • [2] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
    Gupta, Amol
    De Jesus-Acosta, Ana
    Zheng, Lei
    Lee, Valerie
    Kamel, Ihab
    Le, Dung
    Pishvaian, Michael
    Laheru, Daniel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
    Kim, G. P.
    Surinach, A.
    Corvino, F. A.
    Cockrum, P.
    VALUE IN HEALTH, 2019, 22 : S58 - S58
  • [5] Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
    Barzi, Afsaneh
    Miksad, Rebecca
    Surinach, Andy
    Corvino, Frank A.
    Wang, Siqi
    Torres, Aracelis Z.
    Mamlouk, Khalid
    Pulgar, Sonia
    Valderrama, Adriana
    Bekaii-Saab, Tanios
    Ahn, Daniel
    PANCREAS, 2020, 49 (02) : 193 - 200
  • [6] The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
    Su, Yung-Yeh
    Chiang, Nai-Jung
    Tsai, Hui-Jen
    Yen, Chia-Jui
    Shan, Yan-Shen
    Chen, Li-Tzong
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen M.
    CANCER MEDICINE, 2023, 12 (08): : 9496 - 9505
  • [8] Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma
    Kim, George P.
    Surinach, Andy
    Corvino, Frank A.
    Cockrum, Paul
    Belanger, Bruce
    Abushahin, Laith
    FUTURE ONCOLOGY, 2021, 17 (06) : 675 - 688
  • [9] Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients
    O'Reilly, Eileen Mary
    Surinach, Andy
    Dillon, Allison
    Cockrum, Paul
    Yu, Kenneth H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Safety and Efficacy of Liposomal Irinotecan as the Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Real-World Studies
    Chan, Shu-Yen Emily
    Ma, Kevin Sheng-Kai
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S9 - S9
12345